The TGA have announced in an email to stakeholders that they are holding a targeted consultation seeking feedback, closing 7 September 2023, on priorities for future improvement to the Therapeutic Goods Order No. 92 Standard for labels of non-prescription medicines (TGO 92).

A ‘targeted consultation’ is a consultation that is not conducted publicly, but is only conducted with specific stakeholders known to the TGA, such as industry association bodies like CMA, as well as sponsors.

The purpose of this consultation is to seek input before the TGA develop proposals to be included in future public consultation.

The targeted consultation paper outlines some potential TGA identified areas for improvement TGO 92. It also includes targeted consultation on labelling matters regarding large solid oral dosage forms (choking hazard issue) before a public consultation follows.

Please read today’s full tech alert for more information and details about the consultation, including background, highlighted questions relevant to the CM industry, and an overview of current CMA-identified opportunities for labelling improvement.